Manning & Napier Group, LLC Vertex Pharmaceuticals Inc Transaction History

Manning & Napier Group, LLC

$8.76 Billion
Q1 2024

A detailed history of Manning & Napier Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Manning & Napier Group, LLC holds 229,630 shares of VRTX stock, worth $93.7 Million. This represents 1.1% of its overall portfolio holdings.

Number of Shares

229,630

Previous 237,311 3.24%

Holding current value

$93.7 Million

Previous $96.6 Million 0.59%

% of portfolio

1.1%

Previous 1.15%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 15, 2024	SELL	$407.69 - $446.08 $3.13 Million - $3.43 Million	-7,681 Reduced 3.24%	229,630 $96 Million
Q4 2023 Jan 19, 2024	SELL	$343.0 - $410.68 $4.05 Million - $4.85 Million	-11,817 Reduced 4.74%	237,311 $96.6 Million
Q3 2023 Oct 20, 2023	SELL	$338.18 - $362.46 $2.54 Million - $2.72 Million	-7,499 Reduced 2.92%	249,128 $86.6 Million
Q2 2023 Jul 26, 2023	SELL	$314.42 - $351.91 $2.4 Million - $2.68 Million	-7,625 Reduced 2.89%	256,627 $90.3 Million
Q1 2023 Apr 17, 2023	SELL	$283.23 - $323.1 $2.17 Million - $2.47 Million	-7,652 Reduced 2.81%	264,252 $83.3 Million
Q4 2022 Jan 26, 2023	SELL	$285.76 - $321.48 $1.43 Million - $1.6 Million	-4,987 Reduced 1.8%	271,904 $0
Q3 2022 Oct 18, 2022	SELL	$273.83 - $305.53 $853,254 - $952,031	-3,116 Reduced 1.11%	276,891 $80.2 Million
Q2 2022 Jul 12, 2022	SELL	$234.96 - $292.55 $97.5 Million - $121 Million	-414,752 Reduced 59.7%	280,007 $78.9 Million
Q1 2022 Apr 19, 2022	SELL	$221.42 - $260.97 $39.7 Million - $46.8 Million	-179,213 Reduced 20.51%	694,759 $181 Million
Q4 2021 Jan 27, 2022	BUY	$177.01 - $223.45 $184,798 - $233,281	1,044 Added 0.12%	873,972 $192 Million
Q3 2021 Oct 14, 2021	SELL	$181.39 - $202.99 $4.38 Million - $4.9 Million	-24,153 Reduced 2.69%	872,928 $158 Million
Q2 2021 Jul 19, 2021	BUY	$187.49 - $221.1 $7.29 Million - $8.59 Million	38,865 Added 4.53%	897,081 $181 Million
Q1 2021 Apr 28, 2021	BUY	$207.02 - $241.31 $96.4 Million - $112 Million	465,772 Added 118.68%	858,216 $184 Million
Q4 2020 Jan 20, 2021	BUY	$207.01 - $276.09 $69.5 Million - $92.6 Million	335,562 Added 589.93%	392,444 $92.7 Million
Q3 2020 Oct 29, 2020	BUY	$255.65 - $303.1 $722,722 - $856,863	2,827 Added 5.23%	56,882 $15.5 Million
Q2 2020 Jul 10, 2020	BUY	$225.48 - $295.8 $169,110 - $221,850	750 Added 1.41%	54,055 $15.7 Million
Q1 2020 Apr 13, 2020	SELL	$199.77 - $247.81 $33.1 Million - $41.1 Million	-165,932 Reduced 75.69%	53,305 $12.7 Million
Q4 2019 Jan 10, 2020	SELL	$166.71 - $223.91 $3.08 Million - $4.14 Million	-18,480 Reduced 7.77%	219,237 $48 Million
Q3 2019 Oct 10, 2019	SELL	$166.23 - $187.09 $24.2 Million - $27.2 Million	-145,547 Reduced 37.98%	237,717 $40.3 Million
Q2 2019 Jul 24, 2019	BUY	$164.61 - $190.37 $13.6 Million - $15.7 Million	82,670 Added 27.5%	383,264 $70.3 Million
Q1 2019 Apr 10, 2019	SELL	$163.73 - $194.7 $5.27 Million - $6.27 Million	-32,214 Reduced 9.68%	300,594 $55.3 Million
Q4 2018 Jan 24, 2019	SELL	$151.91 - $192.21 $2.78 Million - $3.52 Million	-18,322 Reduced 5.22%	332,808 $55.1 Million
Q3 2018 Oct 10, 2018	SELL	$167.73 - $192.74 $1.77 Million - $2.04 Million	-10,575 Reduced 2.92%	351,130 $67.7 Million
Q2 2018 Jul 13, 2018	BUY	$145.72 - $169.96 $597,452 - $696,836	4,100 Added 1.15%	361,705 $61.5 Million
Q1 2018 May 01, 2018	SELL	$151.6 - $177.13 $82.6 Million - $96.5 Million	-544,897 Reduced 60.38%	357,605 $58.3 Million
Q4 2017 Feb 05, 2018	BUY	$137.28 - $155.55 $124 Million - $140 Million	902,502	902,502 $135 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Manning & Napier Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Manning & Napier Group, LLC with notifications on news.

Account

Manning & Napier Group, LLC Vertex Pharmaceuticals Inc Transaction History